Documentation of diagnosis as evidenced by one or more clinical features consistent with Mycosis Fungoides cutaneous T-Cell lymphoma
Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with requirements of the study
Skin biopsy specimen of representative lesion obtained at screening of study and deemed diagnostic of Mycosis Fungoides by principal investigator
Eligible, in the opinion of the investigator, for low dose TSEBT over the course of two weeks.
Availability of subject to be observed for up to 18 months post-screening evaluation.
Life Expectancy greater than 6 months
You may not be if
Pregnant or breast-feeding females
Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data
Patients diagnosed with Sezary Syndrome. Sezary Syndrome is equivalent to mycosis fungoides that develops to Stage IVA/B with B2 (high blood tumor burden) involvement, and as such requires a more aggressive treatment regimen than Valchlor or TSEBT.
Patients who do not have their disease downgrade to stage IA or IB 30 days following low dose TSEBT.
Underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the patient to undergo treatment
Minimum 3 weeks since prior systematic treatment or phototherapy
Decisionally-impaired individuals, prisoners, and vulnerable populations
Clareo Health | Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides
